The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa
Open accessAbstract
BACKGROUND: In sub-Saharan Africa, the burden of human immunodeficiency virus (HIV)-associated tuberculosis is high. We conducted a trial with a 2-by-2 factorial design to assess the benefits of early antiretroviral therapy (ART), 6-month isoniazid preventive therapy (IPT), or both among HIV-infected adults with high CD4+ cell counts in Ivory Coast. METHODS: We included participants who had HIV type 1 infection and a CD4+ count of less than 800 cells per cubic millimeter and who met no criteria for starting ART according to World Health Organization (WHO) guidelines. Participants were randomly assigned to one of four treatment groups: deferred ART (ART initiation according to WHO criteria), deferred ART plus IPT, early ART (immediate ART initiation), or early ART plus IPT. The primary end point was a composite of diseases included in the case definition of the acquired immunodeficiency syndrome (AIDS), non-AIDS-defining cancer, non-AIDS-defining invasive bacterial disease, or death from any cause at 30 months. We used Cox proportional models to compare outcomes between the deferred-ART and early-ART strategies and between the IPT and no-IPT strategies. RESULTS: A total of 2056 patients (41% with a baseline CD4+ count of ≥500 cells per cubic millimeter) were followed for 4757 patient-years. A total of 204 primary end-point events were observed (3.8 events per 100 person-years; 95% confidence interval [CI], 3.3 to 4.4), including 68 in patients with a baseline CD4+ count of at least 500 cells per cubic millimeter (3.2 events per 100 person-years; 95% CI, 2.4 to 4.0). Tuberculosis and invasive bacterial diseases accounted for 42% and 27% of primary end-point events, respectively. The risk of death or severe HIV-related illness was lower with early ART than with deferred ART (adjusted hazard ratio, 0.56; 95% CI, 0.41 to 0.76; adjusted hazard ratio among patients with a baseline CD4+ count of ≥500 cells per cubic millimeter, 0.56; 95% CI, 0.33 to 0.94) and lower with IPT than with no IPT (adjusted hazard ratio, 0.65; 95% CI, 0.48 to 0.88; adjusted hazard ratio among patients with a baseline CD4+ count of ≥500 cells per cubic millimeter, 0.61; 95% CI, 0.36 to 1.01). The 30-month probability of grade 3 or 4 adverse events did not differ significantly among the strategies. CONCLUSIONS: In this African country, immediate ART and 6 months of IPT independently led to lower rates of severe illness than did deferred ART and no IPT, both overall and among patients with CD4+ counts of at least 500 cells per cubic millimeter. (Funded by the French National Agency for Research on AIDS and Viral Hepatitis; TEMPRANO ANRS 12136 ClinicalTrials.gov number, NCT00495651.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Granich, R. M., Gilks, C. F., Dye, C., De Cock, K. M., & Williams, B. G. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61697-9 · Cited by 1,988
Bacterial Pneumonia in Persons Infected with the Human Immunodeficiency Virus
Hirschtick, R. E., Glassroth, J., Jordan, M. C., Wilcosky, T. C., Wallace, J. M., Kvale, P. A., Markowitz, N., Rosen, M. J., Mangura, B. T., & Hopewell, P. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331305 · Cited by 615
The mortality and pathology of HIV infection in a West African city
Lucas, S. B., Hounnou, A., Peacock, C., Beaumel, A., Djomand, G., NʼGbichi, J.-M., Yeboue, K., Hondé, M., Diomande, M., Giordano, C., et al. (1993) · AIDS · doi:10.1097/00002030-199312000-00005 · Cited by 562
Grinsztejn, B., Hosseinipour, M. C., Ribaudo, H. J., Swindells, S., Eron, J., Chen, Y. Q., Wang, L., Ou, S.-S., Anderson, M., McCauley, M., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70692-3 · Cited by 494
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
Pape, J. W., Jean, S. S., Ho, J. L., Hafner, A., & Johnson, W. D. (1993) · The Lancet · doi:10.1016/0140-6736(93)91817-6 · Cited by 441
Getahun, H., Kittikraisak, W., Heilig, C. M., Corbett, E. L., Ayles, H., Cain, K. P., Grant, A. D., Churchyard, G. J., Kimerling, M., Shah, S., et al. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000391 · Cited by 404
Suthar, A. B., Lawn, S. D., del Amo, J., Getahun, H., Dye, C., Sculier, D., Sterling, T. R., Chaisson, R. E., Williams, B. G., Harries, A. D., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001270 · Cited by 402
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2008) · The Journal of Infectious Diseases · doi:10.1086/586713 · Cited by 399
Self-citationWhalen, C. C., Johnson, J. L., Okwera, A., Hom, D. L., Huebner, R., Mugyenyi, P., Mugerwa, R. D., Ellner, J. J., Nsubuga, P., Vjecha, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371201 · Cited by 396
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Antiretroviral therapy for the prevention of HIV-1 transmission.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600693 · Cited by 1,700
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities
Kharsany, A. B. M., & Karim, Q. A. (2016) · The Open AIDS Journal · doi:10.2174/1874613601610010034 · Cited by 980
Günthard, H. F., Saag, M. S., Benson, C. A., del Rio, C., Eron, J. J., Gallant, J. E., Hoy, J. F., Mugavero, M. J., Sax, P. E., Thompson, M. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.8900 · Cited by 656
Deeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.35 · Cited by 644
Sterling, T. R., Njie, G., Zenner, D., Cohn, D. L., Reves, R., Ahmed, A., Menzies, D., Horsburgh, C. R., Crane, C. M., Burgos, M., et al. (2020) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6901a1 · Cited by 495
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
Swindells, S., Ramchandani, R., Gupta, A., Benson, C. A., Leon-Cruz, J., Mwelase, N., Jean Juste, M. A., Lama, J. R., Valencia, J., Omoz-Oarhe, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806808 · Cited by 363
Global prevalence and burden of HIV-associated neurocognitive disorder: A meta-analysis
Wang, Y., Liu, M., Lu, Q., Farrell, M., Lappin, J. M., Shi, J., Lu, L., & Bao, Y. (2020) · Neurology · doi:10.1212/wnl.0000000000010752 · Cited by 348
Effect of Universal Testing and Treatment on HIV Incidence — HPTN 071 (PopART)
Hayes, R. J., Donnell, D., Floyd, S., Mandla, N., Bwalya, J., Sabapathy, K., Yang, B., Phiri, M., Schaap, A., Eshleman, S. H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814556 · Cited by 337
Ford, N., Shubber, Z., Meintjes, G., Grinsztejn, B., Eholie, S., Mills, E. J., Davies, M.-A., Vitoria, M., Penazzato, M., Nsanzimana, S., et al. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(15)00137-x · Cited by 327
Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades
Levi, J., Raymond, A., Pozniak, A., Vernazza, P., Kohler, P., & Hill, A. (2016) · BMJ Global Health · doi:10.1136/bmjgh-2015-000010 · Cited by 327
Benefits and risks of rapid initiation of antiretroviral therapy
Ford, N., Migone, C., Calmy, A., Kerschberger, B., Kanters, S., Nsanzimana, S., Mills, E. J., Meintjes, G., Vitoria, M., Doherty, M., et al. (2018) · AIDS · doi:10.1097/qad.0000000000001671 · Cited by 291
Koenig, S. P., Dorvil, N., Dévieux, J. G., Hedt-Gauthier, B. L., Riviere, C., Faustin, M., Lavoile, K., Perodin, C., Apollon, A., Duverger, L., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002357 · Cited by 287
Segal, L. N., Clemente, J. C., Li, Y., Ruan, C., Cao, J., Danckers, M., Morris, A., Tapyrik, S., Wu, B. G., Diaz, P., et al. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.03.003 · Cited by 160
Fox, M. P., Bor, J., Brennan, A. T., MacLeod, W. B., Maskew, M., Stevens, W. S., & Carmona, S. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002589 · Cited by 103
Katuramu, R., Kamya, M. R., Sanyu, N., Armstrong-Hough, M., & Semitala, F. C. (2020) · Implementation Science Communications · doi:10.1186/s43058-020-00025-5 · Cited by 9
Steinert, J. I., Khan, S., Mlambo, K., Walsh, F. J., Mafara, E., Lejeune, C., Wong, C., Hettema, A., Ogbuoji, O., Vollmer, S., et al. (2020) · eLife · doi:10.7554/elife.58487 · Cited by 7
Steinert, J. I., Khan, S., Mafara, E., Wong, C., Mlambo, K., Hettema, A., Walsh, F. J., Lejeune, C., Mazibuko, S., Okello, V., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03241-9 · Cited by 6
Boeke, C., Khan, S., Walsh, F., Hettema, A., Lejeune, C., Spiegelman, D., Okello, V, Harwell, J., Mazibuko, S., & Bärnighausen, T. (2021) · HIV Medicine · doi:10.1111/hiv.12941 · Cited by 2
Metadata
- Authors
- The TEMPRANO ANRS 12136 Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-27
- Volume
- 373
- Issue
- 9
- Pages
- 808-822
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2403671454
- Cited by
- 1,242
- References
- 28
- FWCI
- 124.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.